3-(5-Phenylthiophen-3-yl)propanoic acid | 194142-10-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(5-Phenylthiophen-3-yl)propanoic acid
• CAS: 194142-10-4
• 化学式: C₁₃H₁₂O₂S
• 分子量: 232.303
• InChiKey: IEZCYHIPSMPBMH-UHFFFAOYSA-N

物化性质

• 沸点：
  393.6±27.0 °C(Predicted)
• 密度：
  1.234±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  65.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  甲醇 、 3-(5-Phenylthiophen-3-yl)propanoic acid 在 硫酸 作用下， 以94%的产率得到Methyl 3-(5-phenylthiophen-3-yl)propanoate
  参考文献：
  名称：

  Synthesis and structure–activity relationships of 5-phenylthiophenecarboxylic acid derivatives as antirheumatic agents

  摘要：

  5-(Phenylthiophene)-3-carboxylic acid (2a), a metabolite of esonarimod (1), which was developed as a new antirheumatic drug, was considered as a lead compound for new antirheumatic drugs. A new series of 2a derivatives were synthesized and their characteristic pharmacological effects, that is their antagonistic effect toward interleukin (IL)-1 in mice and the suppressive effect against adjuvant-induced arthritis (AIA) in rats, were evaluated and compared with those of 1. The structure-activity relationships indicated that [5-(4-bromophenyl)- thiophen-3-yl]acetic acid (5d), methyl [5-(4-chlorophenyl)-thiophen-3-yl]acetate acid (5d), and methyl [5-(4-bromophenyl)-thiophen-3-yl]acetate (5i) suppressed AIA more potently than 1 and all of the other synthesized compounds. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.08.009
• 作为产物：
  描述：

  2-acetylthiomethyl-3-benzoylpropionic acid 在 六甲基磷酰三胺 、 sodium hydroxide 、 lithium aluminium tetrahydride 、 氯化亚砜 、 硫酸 、 sodium 、 2,3-二氯-5,6-二氰基-1,4-苯醌 、 sodium chloride 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 乙醇 、 水 、 二甲基亚砜 、 苯 为溶剂， 反应 14.0h， 生成 3-(5-Phenylthiophen-3-yl)propanoic acid
  参考文献：
  名称：

  Synthesis and structure–activity relationships of 5-phenylthiophenecarboxylic acid derivatives as antirheumatic agents

  摘要：

  5-(Phenylthiophene)-3-carboxylic acid (2a), a metabolite of esonarimod (1), which was developed as a new antirheumatic drug, was considered as a lead compound for new antirheumatic drugs. A new series of 2a derivatives were synthesized and their characteristic pharmacological effects, that is their antagonistic effect toward interleukin (IL)-1 in mice and the suppressive effect against adjuvant-induced arthritis (AIA) in rats, were evaluated and compared with those of 1. The structure-activity relationships indicated that [5-(4-bromophenyl)- thiophen-3-yl]acetic acid (5d), methyl [5-(4-chlorophenyl)-thiophen-3-yl]acetate acid (5d), and methyl [5-(4-bromophenyl)-thiophen-3-yl]acetate (5i) suppressed AIA more potently than 1 and all of the other synthesized compounds. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.08.009

文献信息

• NOUVELLE UTILISATION ET NOUVEAUX DERIVES DE L'IMIDAZOLE, LEUR PROCEDE DE PREPARATION, LES NOUVEAUX INTERMEDIAIRES OBTENUS, LEUR APPLICATION A TITRE DE MEDICAMENTS ET LES COMPOSITIONS PHARMACEUTIQUES LES RENFERMANT
  申请人：Aventis Pharma S.A.

  公开号：EP0776325B1

  公开（公告）日：2002-11-20
• [EN] NOVEL USE AND NOVEL DERIVATIVES OF IMIDAZOLE, METHOD FOR PREPARING SAME, NOVEL INTERMEDIATES THUS OBTAINED, MEDICINAL APPLICATIONS OF SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME<br/>[FR] NOUVELLE UTILISATION ET NOUVEAUX DERIVES DE L'IMIDAZOLE, LEUR PROCEDE DE PREPARATION, LES NOUVEAUX INTERMEDIAIRES OBTENUS, LEUR APPLICATION A TITRE DE MEDICAMENTS ET LES COMPOSITIONS PHARMACEUTIQUES LES RENFERMANT
  申请人：ROUSSEL UCLAF

  公开号：WO1996004276A1

  公开（公告）日：1996-02-15

  (EN) Novel products of formula (I), wherein R1 is hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, formyl, cycloalkyl optionally interrupted by heteroatoms, R2 and R3 are halogen, mercapto, acyl, carboxy, nitro, cyano, amino, carbamoyl, R4, -OR4, and R4 are hydrogen, alkyl, alkenyl, alkynyl, acyl, amino, -(CH2)m1-S(O)m2-X-R10, wherein m1 = 0-4, m2 = 0-2, X is a single bond or -NH-, -NH-CO-, -NH-CO-NH- and R10 is alkyl, alkenyl or aryl, and Y is optionally substituted aryl, said products being obtained in all the isomeric forms, their salts, and their novel use as medicines.(FR) L'invention concerne la nouvelle utilisation et des nouveaux produits de formule (I) dans lesquels: R1 représente hydryoxyle, alkyle, alkényle, alkynyle, alcoxy, alkylthio, formyle, cycloalkyle, éventuellement interrompu par hétéroatomes, R2, R3 représentent notamment halogène, mercapto, acyle, carboxy, nitro, cyano, amino, carbamoyle, R4, -OR4 avec R4 représente notamment hydrogène, alkyle, alkényle, alkynyle, acyle, amino, -(CH2)m1-S(O)m2-X-R10 avec ml = 0 à 4, m2 = 0 à 2, X représente simple liaison ou -NH-, -NH-CO-, -NH-CO-NH-, et R10 représente alkyle, alkényle ou aryle, et Y représente aryle éventuellement substitué, ces produits étant sous toutes les formes isomères et les sels, à titre de médicaments.
• Synthesis and structure–activity relationships of 5-phenylthiophenecarboxylic acid derivatives as antirheumatic agents
  作者：Toshiya Noguchi、Masahiro Hasegawa、Kazuyuki Tomisawa、Morihiro Mitsukuchi

  DOI：10.1016/j.bmc.2003.08.009

  日期：2003.11

  5-(Phenylthiophene)-3-carboxylic acid (2a), a metabolite of esonarimod (1), which was developed as a new antirheumatic drug, was considered as a lead compound for new antirheumatic drugs. A new series of 2a derivatives were synthesized and their characteristic pharmacological effects, that is their antagonistic effect toward interleukin (IL)-1 in mice and the suppressive effect against adjuvant-induced arthritis (AIA) in rats, were evaluated and compared with those of 1. The structure-activity relationships indicated that [5-(4-bromophenyl)- thiophen-3-yl]acetic acid (5d), methyl [5-(4-chlorophenyl)-thiophen-3-yl]acetate acid (5d), and methyl [5-(4-bromophenyl)-thiophen-3-yl]acetate (5i) suppressed AIA more potently than 1 and all of the other synthesized compounds. (C) 2003 Elsevier Ltd. All rights reserved.